Chemistry:Icrucumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | VEGFR-1 |
| Clinical data | |
| Other names | IMC-18F1 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6514H10024N1756O2032S42 |
| Molar mass | 146796.63 g·mol−1 |
  (what is this?) (verify) | |
Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors.[1][2]
Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials.[3]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/icrucumab.pdf.
- ↑ "Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study". Invest New Drugs 32 (2): 303–11. April 2014. doi:10.1007/s10637-013-9998-8. PMID 23903897.
- ↑ Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov
 |  |
